PMID- 38031962
OWN - NLM
STAT- Publisher
LR  - 20231130
IS  - 1755-5949 (Electronic)
IS  - 1755-5930 (Linking)
DP  - 2023 Nov 30
TI  - Telemedicine during the COVID-19 epidemic improves outcomes in children with 
      tuberous sclerosis complex: A 1206 visits retrospective cohort study.
LID - 10.1111/cns.14549 [doi]
AB  - AIMS: To evaluate the benefits of telemedicine in children with tuberous 
      sclerosis complex during the COVID-19 pandemic. METHODS: A retrospective cohort 
      study was conducted, comparing telemedicine and in-person visits within the 
      timeframe spanning from June 1, 2021, to June 1, 2022. Disparities in 
      demographics, emergency visits, hospitalizations, adverse effects (AEs) 
      associated with sirolimus, and the incidence of drug-refractory epilepsy (DRE) 
      between telehealth and in-person care were assessed. Additionally, distinctions 
      between audio and video telehealth, as well as varying frequencies of telehealth 
      encounters, were investigated and reported as odds ratios (ORs). RESULTS: A total 
      of 378 patients with 1206 visits were included, of which 137 were telemedicine 
      patients and 241 were in-person patients. The median age was 5.0 years (IQR 
      2.8-10.0 years). There were 197 males (52.12%), 691 in-person visits (57.30%), 
      and 515 telemedicine visits (42.70%). Children under 12 years old, those farther 
      away from the center, mothers with more than 12 years of education, and children 
      treated with sirolimus were more likely to visit via telemedicine. Telehealth was 
      associated with significantly fewer emergency visits, hospitalizations, AEs of 
      sirolimus, and DRE. With 10 or more visits, the incidence of emergency visits, 
      hospitalization, and DRE was significantly reduced. CONCLUSION: Telemedicine 
      visits are almost as close in number as in-person visits. Younger patients, 
      patients in remote areas, and mothers with higher education levels are more 
      willing to complete telemedicine visits. Telemedicine visits were associated with 
      a significantly lower number of emergency visits, hospitalizations, and AEs of 
      sirolimus. Patients with more than 10 visits per year seemed to have better 
      clinical outcomes.
CI  - (c) 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & 
      Sons Ltd.
FAU - Wang, Xia
AU  - Wang X
AD  - Department of Neonatology, Xinhua Hospital Affiliated to Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Wang, Ji
AU  - Wang J
AUID- ORCID: 0000-0003-0590-0035
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Du, Xiaonan
AU  - Du X
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Yu, Lifei
AU  - Yu L
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Zhou, Yuanfeng
AU  - Zhou Y
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Zhou, Shuizhen
AU  - Zhou S
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
FAU - Ding, Yifeng
AU  - Ding Y
AUID- ORCID: 0000-0002-4185-6628
AD  - Department of Neurology, National Children Medical Center, Children's Hospital of 
      Fudan University, Shanghai, China.
LA  - eng
GR  - 81803256/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20231130
PL  - England
TA  - CNS Neurosci Ther
JT  - CNS neuroscience & therapeutics
JID - 101473265
SB  - IM
OTO - NOTNLM
OT  - COVID-19
OT  - children
OT  - epilepsy
OT  - telemedicine
OT  - tuberous sclerosis complex
EDAT- 2023/11/30 12:42
MHDA- 2023/11/30 12:42
CRDT- 2023/11/30 06:40
PHST- 2023/11/02 00:00 [revised]
PHST- 2023/02/14 00:00 [received]
PHST- 2023/11/20 00:00 [accepted]
PHST- 2023/11/30 12:42 [medline]
PHST- 2023/11/30 12:42 [pubmed]
PHST- 2023/11/30 06:40 [entrez]
AID - 10.1111/cns.14549 [doi]
PST - aheadofprint
SO  - CNS Neurosci Ther. 2023 Nov 30. doi: 10.1111/cns.14549.